Experts are showing a sharp conflict of opinion over the effectiveness and need for the existence of Korea's system that exempts new drugs from receiving pharmacoeconomic evaluations.

The PE exemption system, which was introduced in 2015, was implemented to improve access to new drugs for patients with severe and rare diseases. However, conflict has been rising on whether to abolish/reduce or continue the operation of the system after making improvements.

Those who are in favor of the PE exemption system argue that the system should be more actively implemented but the process strengthened to increase patient access to treatments, while opponents argue that the system makes overs